68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.	Esthesioneuroblastoma, Olfactory, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Pituitary Neoplasms, brain disorder, capillary hemangioma, central nervous system cancer, central nervous system disorder, cranial nerve neuropathy, endocrine system disorder, epithelial neoplasm, glioma, hemangioblastoma, hemangioma, hypothalamic disorder, hypothalamic neoplasm, malignant endocrine neoplasm, medulloblastoma, meningioma, neoplasm, nervous system disorder, neuroblastoma, neuroendocrine neoplasm, neuroepithelial neoplasm, olfactory nerve disorder, paraganglioma, pituitary gland adenoma, pituitary gland disorder, primitive neuroectodermal tumor, supratentorial cancer, tumor of meninges, vascular cancer	Recruiting	Phase 4	2025-11-21		NCT04081701

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis Pharmaceuticals	432
Weill Medical College of Cornell University	276

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Weill Cornell Medicine	New York	United States	122